×
About 4,280 results

ALLMedicine Immunodeficiencies Center

Research & Reviews  2,045 results

Jeffrey's insights: Jeffrey Modell Foundation's global genetic sequencing pilot program...
https://doi.org/10.1007/s12026-020-09131-x
Immunologic Research; Quinn J, Modell V et. al.

May 26th, 2020 - Primary immunodeficiencies (PI) are genetic defects of the immune system that result in chronic and often life-threatening infections and/or life-threatening autoimmunity if not diagnosed and treated. Patients with a suspected PI, but without a ge...

Incidence of SCID in Germany from 2014 to 2015 an ESPED* Survey on Behalf of the API***...
https://doi.org/10.1007/s10875-020-00782-x
Journal of Clinical Immunology; Shai S, Perez-Becker R et. al.

May 25th, 2020 - Severe combined immunodeficiencies (SCID) are a heterogeneous group of fatal genetic disorders, in which the immune response is severely impaired. SCID can be cured if diagnosed early. We aim to determine the incidence of clinically defined SCID c...

Malignancy post-hematopoietic stem cell transplant in patients with primary immunodefic...
https://doi.org/10.1080/1744666X.2020.1763792
Expert Review of Clinical Immunology; Lum SH, Slatter MA

May 21st, 2020 - Hematopoietic cell transplantation (HCT) is a curative treatment for an expanding number of primary immunodeficiencies (PIDs). Malignancies are more common in patients with PID than in the general population, and this review will discuss whether a...

Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?
https://doi.org/10.1007/s00439-020-02180-0
Human Genetics; Ku CL, Chi CY et. al.

May 16th, 2020 - Anti-cytokine autoantibodies may cause immunodeficiency and have been recently recognized as 'autoimmune phenocopies of primary immunodeficiencies' and are found in particular, but not exclusively in adult patients. By blocking the cytokine's biol...

From Dysgammaglobulinemia to Autosomal-Dominant Activation-Induced Cytidine Deaminase D...
https://doi.org/10.1016/j.jpeds.2020.03.024
The Journal of Pediatrics; Fadlallah J, Chentout L et. al.

May 14th, 2020 - The genetic investigation of a family presenting with a dominant form of hyper IgM syndrome published in 1963 and 1975 revealed a R190X nonsense mutation in activation-induced cytidine deaminase. This report illustrates the progress made over 6 de...

see more →

Guidelines  1 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  2,133 results

Jeffrey's insights: Jeffrey Modell Foundation's global genetic sequencing pilot program...
https://doi.org/10.1007/s12026-020-09131-x
Immunologic Research; Quinn J, Modell V et. al.

May 26th, 2020 - Primary immunodeficiencies (PI) are genetic defects of the immune system that result in chronic and often life-threatening infections and/or life-threatening autoimmunity if not diagnosed and treated. Patients with a suspected PI, but without a ge...

Incidence of SCID in Germany from 2014 to 2015 an ESPED* Survey on Behalf of the API***...
https://doi.org/10.1007/s10875-020-00782-x
Journal of Clinical Immunology; Shai S, Perez-Becker R et. al.

May 25th, 2020 - Severe combined immunodeficiencies (SCID) are a heterogeneous group of fatal genetic disorders, in which the immune response is severely impaired. SCID can be cured if diagnosed early. We aim to determine the incidence of clinically defined SCID c...

Malignancy post-hematopoietic stem cell transplant in patients with primary immunodefic...
https://doi.org/10.1080/1744666X.2020.1763792
Expert Review of Clinical Immunology; Lum SH, Slatter MA

May 21st, 2020 - Hematopoietic cell transplantation (HCT) is a curative treatment for an expanding number of primary immunodeficiencies (PIDs). Malignancies are more common in patients with PID than in the general population, and this review will discuss whether a...

Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?
https://doi.org/10.1007/s00439-020-02180-0
Human Genetics; Ku CL, Chi CY et. al.

May 16th, 2020 - Anti-cytokine autoantibodies may cause immunodeficiency and have been recently recognized as 'autoimmune phenocopies of primary immunodeficiencies' and are found in particular, but not exclusively in adult patients. By blocking the cytokine's biol...

From Dysgammaglobulinemia to Autosomal-Dominant Activation-Induced Cytidine Deaminase D...
https://doi.org/10.1016/j.jpeds.2020.03.024
The Journal of Pediatrics; Fadlallah J, Chentout L et. al.

May 14th, 2020 - The genetic investigation of a family presenting with a dominant form of hyper IgM syndrome published in 1963 and 1975 revealed a R190X nonsense mutation in activation-induced cytidine deaminase. This report illustrates the progress made over 6 de...

see more →

News  75 results

Spotting immunodeficiency in the pediatric dermatology clinic
https://www.mdedge.com/dermatology/article/210332/rare-diseases/spotting-immunodeficiency-pediatric-dermatology-clinic?channel=39212
Jim Kling

Oct 17th, 2019 - SEATTLE – Immunodeficiency in children can look much like eczematous dermatitis. Be aware of this potential diagnosis.

FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies
https://www.medscape.com/viewarticle/915280

Jul 4th, 2019 - The US Food and Drug Administration (FDA) has approved a 20% immune globulin solution for subcutaneous injection (Xembify, Grifols) to treat primary immunodeficiencies in patients as young as 2 years old, according to a company statement. The appr...

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Novel transplant regimen improves survival in primary immunodeficiency
https://www.mdedge.com/hematology-oncology/article/195803/transplantation/novel-transplant-regimen-improves-survival?channel=50521
Sharon Worcester

Mar 6th, 2019 - HOUSTON – Allogeneic hematopoietic stem cell transplantation (allo-HCT) following a novel reduced-intensity conditioning regimen was largely successful in a heterogeneous cohort of 29 adults and children with primary immunodeficiency in a prospect.

A ‘highly effective’ strategy for haplo-HSCT
https://www.mdedge.com/hematology-oncology/article/184883/transplantation/highly-effective-strategy-haplo-hsct
Jen Smith

Jun 27th, 2018 - Daria Pagliara, MD, PhD STOCKHOLM—Researchers have identified a “highly effective” transplant strategy for pediatric patients with primary immunodeficiencies who lack a suitable HLA-compatible donor, according to a speaker at the 23rd Congress of.

see more →

Patient Education  3 results see all →